The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will have the responsibility to project manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage the collection of the already existing and promising Midatech Ltd products or product lines in Life Sciences. PharMida will be headed by Fritz Buhler as chairman, and Jan Mous as CEO.
Mr Buhler, Chairman of PharMida, is professor of pharmaceutical medicine and pathophysiology as well as of internal medicine and cardiology at the Faculty of Medicine, Universities of Basel. Dr Mous, was most recently president and CEO of IntegraGen, and prior to that he held the position of chief scientific officer and was member of the executive board of Lion bioscience.
Thomas Rademacher, founder and chairman of Midatech Group, said: “This is an extremely important step in the development of Midatech and its nanoparticle technology. It is a great privilege to be partnering with such a high calibre team, who between them bring an unrivalled level of expertise and experience in the pharmaceutical sector.
“I am looking forward to working with Mr Buhler and Dr Mous to develop Midatech’s innovative nanoparticle technology to its full potential.”